- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00830531
Pilot Study of Bumetanide for Newborn Seizures
Pilot Study of Bumetanide for Newborn Seizures: A Phase I Study of Pharmacokinetics and Safety of Bumetanide for Neonatal Seizures
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Seizures occur more often during the newborn period (2-3.5 per 1000 live births) than at any later age. Neonatal seizures can lead to frequent and serious long-term consequences in survivors, such as later epilepsy and significant cognitive and motor disabilities. Unfortunately there are no completely effective drugs to treat neonatal seizures. Anti-epileptic drugs (AEDs) currently used to treat neonatal seizures are generally ineffective and have significant potential for side effects. Furthermore, many of these AEDs have never been tested in a randomized study. Numerous experts have thus emphasized in the last few years the urgent need for randomized trials of potential new treatments for neonatal seizures. The investigators are conducting a pilot study of the drug bumetanide as one such potential and novel treatment. Bumetanide is a commercially available drug that has been used safely in newborns as a diuretic for many years with minimal side effects. Recent basic science research in animals has shown bumetanide to be very effective in reducing seizures in neonatal animals by blocking a specific chloride importer which is highly expressed in neonates but not in children and adults (1). Moreover, these experimental studies have shown bumetanide to be particularly effective against seizures when used in combination with phenobarbital (PB), which is the standard first drug given to treat neonatal seizures (2).
The investigators will conduct a randomized, double-blind, controlled, dose escalation study of BTN as add-on therapy to treat refractory seizures caused by HIE, focal or multi-focal stroke, intracranial hemorrhage, CNS infection, genetic syndrome, focal or diffuse brain malformation, idiopathic or presumed genetic etiology of seizures, or metabolic disorder other than electrolyte disturbances or those caused by renal failure not controlled by an initial loading dose of PB. The trial will test the feasibility of early enrollment of newborns with HIE, rapid application of a full montage EEG, and continuous review of EEG data to detect refractory seizures as soon as they occur following an initial loading dose of PB. When an EEG-proven seizure occurs at least 30 minutes following a loading dose of PB, the newborn will be randomized to receive either BTN or placebo in conjunction with a loading dose of PB. Clinical, laboratory and continuous EEG monitoring data obtained after BTN administration will be analyzed to determine the pharmacokinetics (3) and safety of BTN by comparing data from treatment and standard therapy groups. This study addresses important challenges in trial design and sets the stage for trials to improve treatment of neonatal seizures. Data from this pilot study will be used to guide design of a planned Phase III multicenter trial to test the efficacy of BTN to control refractory neonatal seizures.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
Boston, Massachusetts, United States, 02111
- Tufts Floating Hospital for Children at Tufts Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- newborns with a post-conceptional age of 33-44 weeks
condition with risk for seizure:
- asphyxia
- intracranial hemorrhage
- suspected or confirmed stroke
- CNS infection
- genetic syndrome
- focal or diffuse brain malformation
- idiopathic or presumed genetic etiology of seizures
- metabolic disorder other than electrolyte disturbances or those caused by renal failure
- suspected clinical seizure
Exclusion Criteria:
- have transient metabolic abnormalities (e.g., transient hypocalcemia) as the sole cause of seizures
- are receiving ECMO (extracorporeal membrane oxygenation) therapy because of alteration of bumetanide pharmacokinetics by ECMO
- have contraindications to bumetanide (as determined by treating physician)
- have received diuretics such as furosemide or BTN
- newborns with a total serum bilirubin > 15 mg/dL at enrollment
- newborns given ≥ 40mg/kg of phenobarbital
- loading doses of AEDs other than phenobarbital (those who receive levetiracetam are still eligible since levetiracetam does not affect bumetanide pharmacokinetics)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
Standard phenobarbital combined with either 0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the status of the dose escalation design.
|
Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
Other Names:
|
PLACEBO_COMPARATOR: 2
Standard phenobarbital therapy combined with normal saline as placebo for bumetanide
|
Normal Saline as placebo for bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary outcome is determination of the pharmacokinetics and safety of bumetanide in newborns with refractory seizures.
Time Frame: 6-7 years are anticipated for the collection of the neonatal data
|
The investigators will determine the dose exposure, half-life, volume of distribution and clearance of bumetanide in newborns with refractory seizures.
The investigators will determine if there is a significant effect of hepatic dysfunction or hypothermia on bumetanide pharmacokinetics.
For evaluation of safety, the rate of adverse events will be compared between treatment and control groups.
|
6-7 years are anticipated for the collection of the neonatal data
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A secondary outcome is determination of the feasibility of the study design to test antiepileptic drugs to treat neonatal seizures caused by acute hypoxic-ischemic encephalopathy in a clinical trial.
Time Frame: 6-7 years are anticipated for collection of the neonatal data
|
The investigators will determine the feasibility of enrolling and randomizing newborns early in the course of their refractory seizures.
|
6-7 years are anticipated for collection of the neonatal data
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Janet Soul, MD,CM, Boston Children's Hospital
Publications and helpful links
General Publications
- Dzhala VI, Talos DM, Sdrulla DA, Brumback AC, Mathews GC, Benke TA, Delpire E, Jensen FE, Staley KJ. NKCC1 transporter facilitates seizures in the developing brain. Nat Med. 2005 Nov;11(11):1205-13. doi: 10.1038/nm1301. Epub 2005 Oct 9.
- Dzhala VI, Brumback AC, Staley KJ. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model. Ann Neurol. 2008 Feb;63(2):222-35. doi: 10.1002/ana.21229.
- Li Y, Cleary R, Kellogg M, Soul JS, Berry GT, Jensen FE. Sensitive isotope dilution liquid chromatography/tandem mass spectrometry method for quantitative analysis of bumetanide in serum and brain tissue. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Apr 15;879(13-14):998-1002. doi: 10.1016/j.jchromb.2011.02.018. Epub 2011 Feb 19.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CURE 07120492
- 1R01NS066929-01A1 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seizures
-
Eisai Inc.CompletedPartial Onset Seizures | Primary Generalized Tonic-Clonic Seizures | Secondarily Generalized SeizuresUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedGeneralized Tonic Clonic SeizuresKorea, Republic of, United States, Austria, Serbia, India, Spain, Poland, Malaysia, China, Bulgaria, Denmark, Greece, Hungary, United Kingdom, Belarus, France, Montenegro, Philippines, Romania, Russian Federation, Slovakia, Ukraine, Lebano... and more
-
Lundbeck LLCCompletedAdult Refractory Complex Partial SeizuresUnited States
-
University Hospital, BordeauxCompletedPsychogenic Nonepileptic Seizures (PNESs)France
-
Xenon Pharmaceuticals Inc.Worldwide Clinical TrialsRecruitingPrimary Generalized Tonic-Clonic SeizuresUnited States, Australia, Bulgaria, Poland, Czechia, Canada, Portugal, Croatia, Italy, Spain
-
UCB Biopharma SRLRecruitingStereotypical Prolonged SeizuresUnited States, Bulgaria, China, Czechia, Germany, Hungary, Italy, Japan, Poland, Spain, United Kingdom, France, Australia
-
ValexfarmCompletedEpilepsy | Complex Partial Seizures | Simple Partial Seizures | Partial Seizures With Secondary GeneralizationRussian Federation
-
UCB Biopharma SRLEnrolling by invitationStereotypical Prolonged SeizuresUnited States, Bulgaria, China, Czechia, Germany, Hungary, Italy, Japan, Poland, Spain, United Kingdom, Australia
-
Central Hospital, Nancy, FranceCompletedPsychogenic Non-epileptic SeizuresFrance
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedEpilepsy, Partial Seizures | Epilepsy, Primary Generalized Tonic-Clonic SeizuresUnited States, Korea, Republic of, Taiwan, Lebanon, Singapore, Malaysia, China, Spain, Bulgaria, Czechia, United Kingdom, Israel, Russian Federation, France, Belarus, Belgium, Bosnia and Herzegovina, Germany, Greece, Hungary, India and more
Clinical Trials on Bumetanide
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyTerminatedAutism Spectrum Disorder (ASD)Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
-
University Hospital, BrestCompleted
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyTerminatedAutism Spectrum Disorder (ASD)Spain, Hungary, Poland, Brazil, France, Italy, Portugal, United Kingdom, Germany, Netherlands
-
University of CincinnatiTerminatedAssessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus DiureticsAcute Decompensated Heart FailureUnited States
-
Centro en Insuficiencia Cardiaca, MexicoUnknownHeart Failure | Congestive Heart FailureMexico
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaWithdrawn
-
Yale UniversityRecruiting
-
B&A TherapeuticsUnknownParkinson DiseaseFrance
-
NeuroPro Therapeutics, Inc.CompletedEpilepsy | Alzheimer Disease | Epilepsy IntractableUnited States
-
VA Office of Research and DevelopmentRecruitingHypertension | Chronic Kidney DiseaseUnited States